Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sarcoma cancer in Oxford was reorganised during the pandemic. Two studies reveal their success and serve as a guide to other units facing the similar challenge of supporting patients.

Virtual consultation with doctor © Shutterstock
The Oxford Sarcoma Service introduced virtual consultations with patients during the pandemic

During the COVID-19 pandemic, unprecedented strain was placed on healthcare systems across the globe. Many patients saw elective surgeries and non-urgent appointments cancelled but essential services like cancer needed to continue to prevent disease progression and reduce mortality.

The Oxford Sarcoma Service at the Nuffield Orthopaedic Centre (one of five nationally approved centres in England for the treatment of rare bone tumours and sarcomas) saw itself urgently needing to reorganise its structure of cancer care.

To ensure continuation of its services whilst minimising transmission among its patients the Oxford Sarcoma Service was re-structured based on the guidelines issued by the National Health Service (NHS) and the British Orthopaedic Oncology Society (BOOS).

A number of changes were implemented without compromising on delivery of a high standard of care to patients, and its experiences have been published in The Journal of Clinical Orthopaedics and Trauma to serve as a guide to similar units managing bone and soft tissue tumours.

Key changes

  • Virtual multidisciplinary team (MDT) meetings: Key enablers i.e. radiologists, pathologists, orthopaedic oncologists and administrative co-ordinators still meet in person with increased interpersonal spacing while other specialists dial in.
  • Avoiding unproductive attendances at hospital: The service triaged patients to an appropriate referral pathway to bring forward urgent intervention and only patients with active disease which warranted urgent surgery were brought to clinics.
  • Telephone or Video consultations, especially for follow-up patients: Surgery was scheduled only on patients on Level 1a/1b and Level 2 priority. Follow up patients, and patients with benign disease, had telephone/video consultations.
  • Use of COVID-free hospital for surgery: A non-public hospital was used to manage COVID-negative cases. All patients had pre-operative screening for COVID-19, no attenders were allowed, and level 2 PPE was employed by the entire surgical team.
  • Intentional postponement of adjuvant therapies for stable cancers: Adjuvant chemotherapy or radiation therapy were postponed for patients with stable cancer to reduce frequency of trips to hospitals where there was increased risk of disease contraction.

This reorganisation, and a tailored approach to patient treatment, meant the Oxford Sarcoma Service was able to provide uninterrupted care to patients and those most in need of surgery were able to go ahead with their operation.

Surgery was performed on 56 patients with bone and soft tissue traumas during the first two months of the pandemic, either in a COVID-free facility or at the reorganised NOC.

Patient outcomes were monitored and the results published in International Orthopaedics 

The majority of patients were recovering well 30 days after their surgery (96.4%), despite some seeing post-operative complications (7.1%). Four patients contracted COVID-19 of which three required escalation of care and two died (3.6%). Patients under 60 years old had significantly fewer complications than those over 60, and patients operated on in the COVID-free facility had fewer complications than those operated on in the index hospital.

"Surgery on cancer patients during the pandemic is associated with risks and if there was a second wave of COVID-19, serious consideration should be given to ways of protecting vulnerable patients," said Raja Bhaskara Rajasekaran, lead author of the studies. "Our approach to restructuring our services and using either COVID-free facilities or delaying treatment where possible could be a valuable lesson to similar cancer services across the world."

 

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.